Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer - Concepedia

Concepedia

Publication | Closed Access

Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer

430

Citations

13

References

2004

Year

Alan N. Gordon, Margaret Tonda, Steven Sun, Wayne Rackoff

Gynecologic Oncology

Pegylated Liposomal DoxorubicinMedicineCancer ManagementGynecologyLong-term Survival AdvantageCancer TreatmentOncologyRadiation OncologyGynecology OncologyPhase 3Ovarian Cancer

References

	Year	Citations

Page 1